HORMONE SENSITIVE

Astra's Enhertu delays breast cancer in patients with low HER2 levels

The findings, presented in Chicago at the annual meeting of the American Society of Clinical Oncology, could significantly broaden the range of breast cancer patients that might benefit from Enhertu, an antibody-drug conjugate designed to deliver toxic chemotherapy directly to tumors.